Sponsor Dossier
Southern Cross Pharma
Sponsor Dossier for Southern Cross Pharma. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: AGOMELATINE
- Brand: AMISULPRIDE
- Brand: AMOXYCLAV DUO
- Brand: ANAGRELIDE
- Brand: ANASTROZOLE
- Brand: APO-AGOMELATINE
- Brand: APO-CLONIDINE
- Brand: APO-FENOFIBRATE
About
Southern Cross Pharma is an Australian Private Company with ABN 47094447677, registered in Victoria and currently active.
Portfolio
Southern Cross Pharma has 82 brands on the ARTG, of which 51 are indexable and 47 carry a Product Information document. 34 brands are PBS-listed, 0 have a PBAC outcome on record, and 2 have an AusPAR on record. Notable brands include AGOMELATINE, AMISULPRIDE, AMOXYCLAV DUO, ANAGRELIDE, ANASTROZOLE, APO-AGOMELATINE, APO-CLONIDINE, APO-FENOFIBRATE, APO-Levetiracetam, APO-LEVOTHYROXINE, APO-LORAZEPAM, APO-MESALAZINE MR.
Therapeutic focus
— Infectious Disease: 11 brands — Neurology: 11 brands — Cardiology: 11 brands — Oncology: 9 brands — Pain Management: 7 brands — Psychiatry: 7 brands — Dermatology: 7 brands — Gastroenterology: 4 brands — Endocrinology: 3 brands — Haematology: 3 brands — Musculoskeletal: 3 brands — Reproductive Health: 2 brands — Renal: 2 brands — Uncategorised: 1 brand — Other: 1 brand
PBS footprint
34 brands are PBS-listed, with the latest PBS schedule date 2026-11-01.
Regulatory activity
The latest AusPAR is 2017-11-02, across 2 brands with an AusPAR on record.